```html

Zollinger‑Ellison Syndrome‑Associated Gastrinoma

Overview

Zollinger‑Ellison syndrome (ZES) is a rare, hormone‑driven disorder caused by one or more gastrin‑producing tumors called gastrinomas. These tumors are most often found in the pancreas or duodenum and secrete excessive amounts of gastrin, a hormone that stimulates the stomach lining to produce large volumes of gastric acid. The resulting hyperacidity leads to recurrent peptic ulcers, diarrhea, and a host of other gastrointestinal problems.

• Who it affects: Adults of any age, but most cases are diagnosed between 30–60 years. Men and women are equally affected.
• Prevalence: ZES occurs in approximately 0.1–1 per million people worldwide. About 25 % of gastrinomas occur as part of the hereditary condition multiple endocrine neoplasia type 1 (MEN 1). Sporadic (non‑inherited) gastrinomas account for the remaining 75 %.
• Incidence trend: Improved imaging (EUS, CT) and awareness have increased detection rates over the past two decades, but the disease remains rare.

Symptoms

Because gastrinomas produce high levels of gastric acid, symptoms primarily reflect acid‑related injury and malabsorption. The severity varies with tumor size, number, and location.

Gastro‑intestinal symptoms

• Recurrent peptic ulcers – often multiple, located beyond the duodenum (e.g., jejunum) and resistant to standard ulcer therapy.
• Abdominal pain – cramping or burning that may worsen after meals.
• Severe or chronic diarrhea – up to 5–10 watery stools per day due to acid‑induced damage of the intestinal mucosa and inactivation of pancreatic enzymes.
• Steatorrhea (fatty stools) – malabsorption of fat caused by acid‑mediated pancreatic enzyme inactivation.
• Nausea and vomiting – especially after large meals.
• Gastro‑esophageal reflux disease (GERD) – heartburn and regurgitation from excess acid.

Systemic symptoms

• Weight loss – due to malabsorption, chronic diarrhea, and reduced appetite.
• Fatigue – from anemia (iron deficiency) or malnutrition.
• Electrolyte disturbances – low potassium, magnesium, or calcium from chronic diarrhea.

Signs suggestive of a gastrinoma

• Ulcers that fail to heal after 8‑12 weeks of proton‑pump inhibitor (PPI) therapy.
• Ulcers located distal to the duodenum (jejunum, ileum).
• New‑onset ulcer disease after age 50.
• Elevated fasting serum gastrin > 1000 pg/mL (reference < 100 pg/mL).

Causes and Risk Factors

Gastrinomas arise from neuroendocrine cells (G‑cells) in the pancreas or duodenum. The exact mutational events are still under investigation, but several pathways have been identified.

Genetic causes

• MEN 1 syndrome – Germline mutations in the MEN1 tumor suppressor gene (chromosome 11q13) lead to multiple endocrine tumors, including gastrinomas. Approximately 20‑25 % of ZES patients have MEN 1.
• Familial isolated gastrinoma – Rare autosomal‑dominant inheritance with unknown gene(s); accounts for < 1 % of cases.

Environmental and lifestyle factors

• There are no clear lifestyle risk factors (e.g., smoking, alcohol) directly linked to gastrinoma development.
• Chronic H. pylori infection does not cause gastrinomas, but may coexist and exacerbate ulcer disease.

Who is at higher risk?

• Individuals with MEN 1 or a family history of gastrinoma.
• Patients with unexplained, recurrent, distal peptic ulcers.
• People with persistent hypergastrinemia after long‑term PPI use (necessitating further evaluation).

Diagnosis

Diagnosing ZES involves confirming hypergastrinemia, demonstrating acid hypersecretion, and localizing the tumor.

Initial laboratory assessment

• Fasting serum gastrin – Measured after at least an 8‑hour fast. Levels > 1,000 pg/mL are highly predictive of ZES; intermediate values require provocative testing.
• Secretin stimulation test – Intravenous secretin normally suppresses gastrin; in ZES it paradoxically **increases** gastrin ≥ 120 pg/mL above baseline. This test remains the gold standard when fasting gastrin is 100–1,000 pg/mL.
• Gastric pH – A basal pH < 2 confirms acid hypersecretion.
• Other labs – CBC for anemia, electrolytes (especially K⁺, Mg²⁺), iron studies, and vitamin B12.

Imaging studies for tumor localization

1. Endoscopic ultrasound (EUS) – Highly sensitive (up to 85 %) for small (< 2 cm) pancreatic or duodenal lesions.
2. Multiphasic contrast‑enhanced CT or MRI – Detects lesions > 1 cm and assesses metastatic spread to liver or lymph nodes.
3. Somatostatin receptor scintigraphy (Octreoscan®) or ^68Ga‑DOTATATE PET/CT – Functional imaging that exploits high somatostatin‑receptor expression on neuroendocrine tumors; preferred for detecting occult or metastatic disease.
4. Selective arterial calcium stimulation with hepatic venous sampling – Invasive technique used when non‑invasive imaging is inconclusive; calcium injection into arteries triggers a surge of gastrin from the tumor.

Histologic confirmation

If surgical resection is planned, tissue obtained intra‑operatively or via endoscopic fine‑needle aspiration is examined for neuroendocrine markers (chromogranin A, synaptophysin) and Ki‑67 proliferation index, which guides tumor grading.

Treatment Options

Management aims to (1) control gastric acid hypersecretion, (2) eradicate or control the tumor, and (3) address nutritional deficiencies.

Acid‑suppression therapy (first line)

• High‑dose proton‑pump inhibitors (PPIs) – Omeprazole 40–80 mg daily, esomeprazole 40–80 mg, or equivalent. PPIs are the most effective, achieving ulcer healing in > 90 % of patients.
• Potassium‑competitive acid blockers (PCABs) – Vonoprazan (if available) offers rapid, sustained acid suppression and may be useful in refractory cases.
• Life‑long therapy is usually required unless the tumor is completely removed.

Surgical management

Curative surgery is possible for localized gastrinomas, especially when the disease is sporadic.

• Enucleation – Removal of a solitary, small (< 2 cm) tumor while preserving pancreatic tissue.
• Pancreaticoduodenectomy (Whipple procedure) – Recommended for larger duodenal or pancreatic head lesions.
• Distal pancreatectomy – For tumors located in the body/tail of the pancreas.
• Liver metastasectomy – If disease is limited to resectable hepatic lesions.

In MEN 1 patients, surgery is more controversial because of multifocal disease; many clinicians opt for medical control and reserve surgery for symptomatic or rapidly growing tumors.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues – Octreotide or lanreotide bind somatostatin receptors, reducing gastrin secretion and slowing tumor growth. Dose‑adjusted based on symptom control.
• Targeted therapy – Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) have FDA approval for advanced pancreatic neuroendocrine tumors and can be used when disease progresses.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor–positive cells and has shown promising response rates in metastatic gastrinomas.
• Chemotherapy – Reserved for high‑grade (Ki‑67 > 20 %) neuroendocrine carcinomas; regimens include streptozocin‑based combinations.

Lifestyle and supportive measures

• Small, frequent meals low in fat to reduce acid stimulus.
• Avoid NSAIDs, aspirin, and other ulcer‑aggravating drugs.
• Supplement iron, calcium, vitamin D, and B12 if labs indicate deficiency.
• Stay hydrated; oral rehydration solutions may be needed for chronic diarrhea.

Living with Zollinger‑Ellison Syndrome‑Associated Gastrinoma

Long‑term management blends medication adherence, monitoring, and lifestyle tweaks.

Medication adherence

• Take PPIs or PCABs exactly as prescribed—usually before breakfast.
• Carry a short‑acting antacid (e.g., calcium carbonate) for breakthrough symptoms.
• Schedule regular follow‑up labs (gastrin level, vitamin B12, iron studies) every 6–12 months.

Nutrition

• Eat low‑fat, low‑fiber meals 4–6 times per day; fat slows gastric emptying and may worsen diarrhea.
• Incorporate protein‑rich foods (lean poultry, fish, tofu) to support healing.
• Limit caffeine, alcohol, and spicy foods, which increase acid output.
• Consider a dietitian experienced with neuroendocrine tumors for individualized plans.

Monitoring for recurrence

• Imaging (CT/MRI or ^68Ga‑DOTATATE PET) every 12–24 months, or sooner if symptoms change.
• Watch for new ulcer symptoms, unexplained weight loss, or worsening diarrhea—these may signal tumor growth or metastasis.

Psychosocial well‑being

• Join support groups (e.g., NET Patient Foundation) to share experiences.
• Address anxiety or depression with counseling or medication; chronic disease can be emotionally taxing.

Prevention

Because gastrinomas are largely sporadic or genetically predetermined, primary prevention is limited. However, some measures can reduce complications and possibly delay disease manifestation.

• Genetic counseling for individuals with known MEN 1 mutations; early screening (annual fasting gastrin, imaging) may detect tumors before they cause severe symptoms.
• Avoid chronic PPI overuse without supervision—while PPIs control acid, they may mask rising gastrin levels, delaying diagnosis.
• Healthy lifestyle – Maintaining a balanced diet and stable weight supports overall gastrointestinal health, though it does not prevent gastrinoma formation.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems.

• Refractory or perforated peptic ulcers – May cause gastrointestinal bleeding, peritonitis, or need for emergency surgery.
• Severe malabsorption – Chronic diarrhea and steatorrhea can cause protein‑energy malnutrition, vitamin deficiencies, and electrolyte imbalances.
• Gastro‑intestinal bleeding – From ulcer erosion into vessels.
• Metastatic disease – Approximately 60–80 % of gastrinomas metastasize, most often to the liver or regional lymph nodes.
• Osteoporosis – Chronic acid exposure reduces calcium absorption.
• Secondary infections – Acid‑neutralized environment may permit bacterial overgrowth in the small intestine.

When to Seek Emergency Care

Prompt evaluation can prevent life‑threatening complications and improve outcomes.

---

References:

• Mayo Clinic. “Zollinger‑Ellison syndrome.” https://www.mayoclinic.org. Accessed June 2026.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison syndrome.” https://www.niddk.nih.gov.
• American Cancer Society. “Neuroendocrine Tumors of the Pancreas.” https://www.cancer.org. 2024.
• Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison syndrome).” https://my.clevelandclinic.org.
• World Health Organization. “Classification of Neuroendocrine Tumors.” WHO Classification of Tumours, 5th Ed., 2023.
• Strobel O et al. “Management of Gastrinomas and Zollinger‑Ellison Syndrome.” *Journal of Clinical Gastroenterology*, 2022;56(8):635‑645.

```